24 July 2020 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature Review
Ashraf Imam1ACDEF*, Sadi A. Abukhalaf1ABCEF, Riham Imam1BCD, Samir Abu-Gazala1AEF, Hadar Merhav1ACD, Abed Khalaileh1ABCEFDOI: 10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
Table 7 Management and outcomes of the 58 reported kidney transplant patients who encountered COVID-19 compared with previous published studies.
| Variable | This study | Akalin et al. [47] | Alberici et al. [48] | CUKTP [49] | Pooled (mean) |
|---|---|---|---|---|---|
| Baseline Immunosuppression | |||||
| Tacrolimus | 82.7% | 97% | 95% | 93% | 91.9% |
| Mycophenolate mofetil | 79.3% | 86% | 70% | 80% | 78.8% |
| Prednisone | 81% | 94% | 65% | 67% | 77% |
| Azathioprine | 3.4% | 7% | 5.2% | ||
| Management | |||||
| Immunosuppression | |||||
| Held tacrolimus | 47.9% | 21% | 34.4% | ||
| Held mycophenolate mofetil | 80.4% | 86% | 71% | 79.1% | |
| Other Tx | |||||
| Lopinavir/Ritonavir | 20.6% | 79% | 49.8% | ||
| Hydroxychloroquine | 43.1% | 86% | 95% | 86.6% | 77.6% |
| Azithromycin | 15.5% | 46% | 60% | 40.5% | |
| Antibiotics | 41.3% | 55% | 48.1% | ||
| Tocilizumab | 3.4% | 7% | 30% | 7% | 11.8% |
| ICU admission | 19% | 20% | 20% | ||
| MV requirement | 22.4% | 39% | 10% | 27% | 24.6% |
| Outcomes | |||||
| Clinically recovered/Discharged | 62% | 36% | 15% | 53% | 42% |
| Alive but suffers/In hospital | 22.4% | 43% | 60% | 40% | 41.3% |
| Death | 15.5% | 28% | 25% | 7% | 18.8% |